# OnCo record melflufen (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/melflufen/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "melflufen" ;
  schema:name "Melphalan flufenamide"@en ;
  schema:description "A myeloma drug given accelerated approval in 2021 and withdrawn in the US months later when its confirmatory trial suggested it shortened survival."@en ;
  schema:url <https://onco.cc/drugs/melflufen/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Melphalan_flufenamide> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27277739> ;
  schema:citation <https://www.fda.gov/drugs/drug-safety-and-availability/> ;
  onco:status "withdrawn" ;
  onco:tag "failure", "lesson:regulatory" ;
  onco:modality "Peptide-drug conjugate" ;
  schema:alternateName "Pepaxto" ;
  onco:acceleratedApproval "US 2021-02-26: In combination with dexamethasone for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/peptide-drug-conjugate/> ;
  onco:companies <https://onco.cc/companies/oncopeptides/> ;
  onco:terms <https://onco.cc/terms/accelerated-approval/> ;
  onco:trials <https://onco.cc/trials/nct03151811/>, <https://onco.cc/trials/nct04649060/>, <https://onco.cc/trials/nct02963493/> .